Switching TNF-alpha antagonists in rheumatoid arthritis: The experience of the LORHEN registry

Autoimmunity Reviews

Volumn 9, Issue 6, 2010, Pages 465-469

  Caporali, Roberto ^a   Sarzi Puttini, Piercarlo ^b   Atzeni, Fabiola ^b   Gorla, Roberto ^c   Filippini, Matteo ^c   Marchesoni, Antonio ^d   Favalli, Ennio Giulio ^d   Bobbio Pallavicini, Francesca ^a   Montecucco, Carlomaurizio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Rheumatology and Clinical Immunology Unit   (Italy)

^d G Pini Orthopaedic Institute   (Italy)

Author keywords

Anti TNF alpha; DMARDs; Methotrexate; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; MONOCLONAL ANTIBODY; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; DISEASE ACTIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; ITALY; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950300568     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.12.010     Document Type: Review

References (40)

1. Caporali R., Bobbio-Pallavicini F., Filippini M., Gorla R., Marchesoni A., Favalli E.G., et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 8 (2009) 274-280
2. Smolen J.S., Aletaha D., Koeller M., Weisman M.H., and Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 370 (2007) 1861-1874
3. Marchesoni A., Zaccara E., Gorla R., Bazzani C., Sarzi-Puttini P., Atzeni F., et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 1173 (2009) 837-846
4. Bazzani C., Filippini M., Caporali R., Bobbio-Pallavicini F., Favalli E.G., Marchesoni A., et al. Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes. Autoimmun Rev 8 (2009) 260-265
5. van Vollenhoven R.F. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis 66 (2007) 849-851
6. Favalli E.G., Desiati F., Atzeni F., Sarzi-Puttini P., Caporali R., Pallavicini F.B., et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev 8 (2009) 266-273
7. van Vollenhoven R., Harju A., Brannemark S., and Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 62 (2003) 1195-1198
8. Hansen K.E., Hildebrand J.P., Genovese M.C., Cush J.J., Patel S., Cooley D.A., et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 31 (2004) 1098-1102
9. Haraoui B., Keystone E.C., Thorne J.C., Pope J.E., Chen I., Asare C.G., et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 31 (2004) 2356-2359
10. Gómez-Puerta J.A., Sanmartí R., Rodríguez-Cros J.R., and Cañete J.D. Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy. Ann Rheum Dis 63 (2004) 896
11. Bennett A.N., Peterson P., Zain A., Grumley J., Panayi G., and Kirkham B. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology 44 (2005) 1026-1031 (Oxford)
12. Wick M.C., Ernestam S., Lindblad S., Bratt J., Klareskog L., and van Vollenhoven R.F. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 34 (2005) 353-358
13. Cohen G., Courvoisier N., Cohen J.D., Zaltni S., Sany J., and Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 23 (2005) 795-800
14. Gomez-Reino J.J., and Carmona L. BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8 1 (Jan 6 2006) R29 Electronic publication
15. Nikas S.N., Voulgari P.V., Alamanos Y., Papadopoulos C.G., Venetsanopoulou A.I., Georgiadis A.N., et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis 65 (2006) 257-260
16. Hyrich K.L., Lunt M., Watson K.D., Symmons D.P., and Silman A.J. British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56 (2007) 13-20
17. Iannone F., Trotta F., Montecucco C., Giacomelli R., Galeazzi M., Matucci-Cerinic M., et al. GISEA (Gruppo Italiano per lo Studio delle Early Arthritis). Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 66 (2007) 249-252
18. Bombardieri S., Ruiz A.A., Fardellone P., Geusens P., McKenna F., Unnebrink K., et al. Research in Active Rheumatoid Arthritis (ReAct) Study Group. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 46 (2007) 1191-1199 (Oxford)
19. Buch M.H., Bingham S.J., Bejarano V., Bryer D., White J., Reece R., et al. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum 57 (2007) 448-453
20. Furst D.E., Gaylis N., Bray V., Olech E., Yocum D., Ritter J., et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 66 (2007) 893-899
21. Hjardem E., Østergaard M., Pødenphant J., Tarp U., Andersen L.S., Bing J., et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?. Ann Rheum Dis 66 (2007) 1184-1189
22. Karlsson J.A., Kristensen L.E., Kapetanovic M.C., Gülfe A., Saxne T., and Geborek P. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 47 (2008) 507-513 (Oxford)
23. van der Bijl A.E., Breedveld F.C., Antoni C.E., Kalden J.R., Kary S., Burmester G.R., et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 27 (2008) 1021-1028
24. Laas K., Peltomaa R., Kautiainen H., and Leirisalo-Repo M. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. Clin Rheumatol 27 (2008) 927-932
25. Hyrich K.L., Lunt M., Dixon W.G., Watson K.D., and Symmons D.P. BSR Biologics Register. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology 47 (2008) 1000-1005 (Oxford)
26. Scrivo R., Conti F., Spinelli F.R., Truglia S., Magrini L., Di Franco M., et al. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo 61 (2009) 107-117
27. Sarzi-Puttini P., Antivalle M., Marchesoni A., Favalli E.G., Gorla R., Filippini M., et al. Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). Reumatismo 60 (2008) 290-295
28. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
29. Prevoo M.L., van 't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., and van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1995) 44-48
30. Ranza R., Marchesoni A., Calori G., Bianchi G., Braga M., Canazza S., et al. The Italian version of the Functional Disability Index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol 11 (1993) 123-128
31. Valesini G., Montecucco C., and Cutolo M. Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy. Clin Exp Rheumatol 24 (2006) 413-423
32. Schett G. Immune cells and mediators of inflammatory arthritis. Autoimmunity 41 (2008) 224-229
33. Braun A., Takemura S., Vallejo A.N., Goronzy J.J., and Weyand C.M. Lymphotoxin beta-mediated stimulation of synoviocytes in rheumatoid arthritis. Arthritis Rheum 50 (2004) 2140-2150
34. Aggarwal R., Manadan A.M., Poliyedath A., Sequeira W., and Block J.A. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. J Rheumatol 36 (2009) 914-917
35. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheum 34 5 Suppl1 (2005) 12-18
36. Anderson P.J. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34 5 Suppl1 (2005) 19-22
37. Finckh A., Ciurea A., Brulhart L., Möller B., Walker U.A., Courvoisier D., et al. Which subgroup of rheumatoid arthritis patients benefits from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agent?. Ann Rheum Dis (May 15 2009)
38. Smolen J.S., Kay J., Doyle M.K., Landewé R., Matteson E.L., Wollenhaupt J., et al. GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374 (2009) 210-221
39. Singh J.A., Christensen R., Wells G.A., Suarez-Almazor M.E., Buchbinder R., Lopez-Olivo M.A., et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ (Nov 2 2009) 19884297 Electronic publication PubMed PMID
40. Kristensen L.E., Kapetanovic M.C., Gülfe A., Söderlin M., Saxne T., and Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 47 (2008) 495-499 (Oxford)